Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication
Artículo científico (JournalArticle)
Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms
Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell
transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers
as a surrogate measure of relapse is not always helpful; therefore, improved systems to detect
early relapse are needed. We hypothesized that the use of next generation sequencing (NGS)
could be a suitable approach for personalized follow-up post-HSCT. To validate our hypothesis,
we analyzed by NGS, a retrospective set of peripheral blood (PB) DNA samples previously evaluated
by high-sensitive quantitative PCR analysis using insertion/deletion polymorphisms (indel-qPCR)
chimerism engraftment. Post-HCST allelic burdens assessed by NGS and chimerism status showed a
similar time-course pattern. At time of clinical relapse in 8/12 patients, we detected positive NGS-based
minimal residual disease (NGS-MRD). Importantly, in 6/8 patients, we were able to detect NGS-MRD
at time points collected prior to clinical relapse. We also confirmed the disappearance of post-HCST
allelic burden in non-relapsed patients, indicating true clinical specificity. This study highlights the
clinical utility of NGS-based post-HCST monitoring in myeloid neoplasia as a complementary specific
analysis to high-sensitive engraftment testing. Overall, NGS-MRD testing in PB is widely applicable
for the evaluation of patients following HSCT and highly valuable to personalized early treatment
intervention when mixed chimerism is detected., This work was funded by the Government of Navarra, Department of Industry, Energy and
Innovation (Project DIANA, 0011-1411-2017-000028); and supported by CIMA LAB diagnostics research program.
F.P. acknowledges funding from Instituto de Salud Carlos III (ISCIII) PI16/02024, PI17/00701 and PI19/01352
(Co-financed with European Union FEDER funds), CIBERONC CB16/12/00489 (Co-financed with European
Union FEDER funds), MINECO Explora (RTHALMY), Departamento de Salud-Gobierno de Navarra 40/2016 and
Fundación Ramón Areces (PREMAMM).
Project:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) PI16-02024
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI17-00701
,
ISCIII PI19-01352
,
MINECO CB16-12-00489
,
Gobierno de Navarra 0011-1411-2017-000028
,
Gobierno de Navarra 40-2016
View at: https://hdl.handle.net/2454/51962